Genomictree Inc. Genomictree Inc.

Genomictree Inc.

228760

Rang in aandelen #19128
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Aandeelprijs
$6.58
Marktkapitalisatie
$161.41M
Verandering (1 dag)
-0.63%
Verandering (1 jaar)
-50.29%
Land
KR
Handel Genomictree Inc. (228760)

Categorie

Healthcare
Aandelsplitsingen voor Genomictree Inc. (228760)
Het aandeel Genomictree Inc. (symbool: 228760) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 21, 2026.
Eén aandeel 228760 dat vóór Oct 21, 2026 werd gekocht, staat nu gelijk aan 0 aandelen 228760.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
US
1 x3
AU
0 -
NL
0 -
CH